CPT code 90612 denotes a combination intramuscular vaccine that delivers both a trivalent influenza component and an mRNA COVID–19 component in a single 0.32 mL dose (31.7 micrograms). Nationally, combination vaccines that streamline delivery of routine seasonal influenza protection with COVID–19 prevention have implications for immunization workflows, supply chain planning, and preventive care rates.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines clinical context for a one‑dose intramuscular vaccine administered in ambulatory and pharmacy settings, and summarizes what readers will learn: payment and coding benchmarks where available, clinical administration considerations inherent to combination flu/COVID immunizations, and applicable billing guidance. Data not available in the input for specific payer coverage policies, rate benchmarks, associated taxonomies, and ICD‑10 pairings is noted as unavailable.

Readers will gain a concise reference to the code’s clinical meaning, typical sites of service, common modifiers (listed separately in metadata), and where to look for payer‑specific coverage rules. The summary provides a national perspective useful to billing teams, immunization program managers, and policy analysts focused on preventive vaccine delivery and reimbursement logistics.